Clinical results of stereotactic body radiotherapy for Stage I small-cell lung cancer: a single institutional experience
Open Access
- 24 August 2012
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Journal of Radiation Research
- Vol. 54 (1) , 108-112
Abstract
The purpose of this study was to evaluate the treatment outcomes of stereotactic body radiotherapy (SBRT) for Stage I small-cell lung cancer (SCLC). From April 2003 to September 2009, a total of eight patients with Stage I SCLC were treated with SBRT in our institution. In all patients, the lung tumors were proven as SCLC pathologically. The patients' ages were 58–84 years (median: 74). The T-stage of the primary tumor was T1a in two, T1b in two and T2a in four patients. Six of the patients were inoperable because of poor cardiac and/or pulmonary function, and two patients refused surgery. SBRT was given using 7–8 non-coplanar beams with 48 Gy in four fractions. Six of the eight patients received 3–4 cycles of chemotherapy using carboplatin (CBDCA) + etoposide (VP-16) or cisplatin (CDDP) + irinotecan (CPT-11). The follow-up period for all patients was 6–60 months (median: 32). Six patients were still alive without any recurrence. One patient died from this disease and one died from another disease. The overall and disease-specific survival rate at three years was 72% and 86%, respectively. There were no patients with local progression of the lesion targeted by SBRT. Only one patient had nodal recurrence in the mediastinum at 12 months after treatment. The progression-free survival rate was 71%. No Grade 2 or higher SBRT-related toxicities were observed. SBRT plus chemotherapy could be an alternative to surgery with chemotherapy for inoperable patients with Stage I small-cell lung cancer. However, further investigation is needed using a large series of patients.Keywords
This publication has 19 references indexed in Scilit:
- A clinical evaluation of visual feedback-guided breath-hold reproducibility of tumor locationPhysics in Medicine & Biology, 2009
- Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trialThe Lancet Oncology, 2009
- Stereotactic Body Radiotherapy for Oligometastatic Lung TumorsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008
- Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frameInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2005
- Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: The Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101)The Journal of Thoracic and Cardiovascular Surgery, 2005
- Stereotactic hypofractionated radiation therapy for stage I non-small cell lung cancerLung Cancer, 2005
- Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: Its time has comeThe Journal of Thoracic and Cardiovascular Surgery, 2005
- Stereotactic hypofractionated high‐dose irradiation for stage I nonsmall cell lung carcinomaCancer, 2004
- Stereotactic radiotherapy for primary lung cancer and pulmonary metastases: A noninvasive treatment approach in medically inoperable patientsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2004
- Prophylactic Cranial Irradiation for Patients with Small-Cell Lung Cancer in Complete RemissionNew England Journal of Medicine, 1999